{"product_id":"alny-bcg-matrix","title":"(ALNY) Alnylam Pharmaceuticals, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Alnylam Pharmaceuticals, Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. What you see on this page is a real preview of the actual report, not just marketing text, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMVUTTRA 2024 ATTR-CM approval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMVUTTRA’s ATTR-CM label expansion opens a far larger market than hATTR polyneuropathy; the global ATTR-CM market is now measured in the billions, not a niche. In 2024, AMVUTTRA generated about $1.2 billion in net product revenue, showing strong launch traction and high priority inside Alnylam Pharmaceuticals, Inc. It is the clearest Star in the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMVUTTRA hATTR-PN core franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMVUTTRA is Alnylam Pharmaceuticals, Inc.’s original vutrisiran launch in hereditary ATTR polyneuropathy, and it sits in a rare-disease market where Alnylam already has strong specialist access and brand trust. Its once-every-3-month RNAi dosing supports adoption, especially versus less convenient regimens. With strong share and continued growth in 2025, it fits a Star in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMVUTTRA global rollout 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam kept AMVUTTRA in a strong rollout phase in 2025, with U.S. ATTR-CM approval from HELIOS-B data showing a 28% lower risk of all-cause mortality and recurrent cardiovascular events. Wider launch work in Europe, Japan, and other markets expands the treatable pool as ATTR remains widely underdiagnosed. That can keep revenue growth high as diagnosis rates improve and access broadens.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAMVUTTRA earlier-line adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAMVUTTRA is moving earlier in the ATTR pathway after its 2025 FDA approval for ATTR-CM, and that matters because earlier diagnosis can widen the treatable pool and extend time on therapy. In HELIOS-B, 654 patients were enrolled, showing the scale behind this launch. Longer use per patient lifts lifetime revenue, but Alnylam still has to fund heavy field work and education, which fits a Star.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarlier diagnosis supports longer treatment duration.\u003c\/li\u003e\n\u003cli\u003e2025 FDA approval widened the addressable market.\u003c\/li\u003e\n\u003cli\u003e654-patient HELIOS-B backed the launch.\u003c\/li\u003e\n\u003cli\u003eHeavy commercial spend still remains necessary.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eATTR franchise 2025 scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAMVUTTRA is Alnylam Pharmaceuticals, Inc.’s main growth engine in 2025, with ATTR polyneuropathy and ATTR cardiomyopathy now giving the franchise two big demand pools. The U.S. FDA approved its cardiomyopathy use in March 2025, which broadened the label beyond neuropathy and reinforced its RNAi leadership. That scale-up pattern fits a BCG Star: high growth, strong share, and rising commercial momentum.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo-use franchise: neuropathy plus cardiomyopathy\u003c\/li\u003e\n\u003cli\u003eMarch 2025 FDA label expansion\u003c\/li\u003e\n\u003cli\u003eAlnylam’s leading RNAi position\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMVUTTRA Expands Beyond Neuropathy Into a Bigger Heart Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMVUTTRA is Alnylam Pharmaceuticals, Inc.’s Star: 2025 FDA approval in ATTR-CM widened its market from rare neuropathy into a much larger cardiomyopathy pool. 2024 net product revenue was about $1.2 billion, showing strong scale and demand. Its quarterly dosing and HELIOS-B data support faster uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 label\u003c\/td\u003e\n\u003ctd\u003eATTR-CM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003eAbout $1.2 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHELIOS-B\u003c\/td\u003e\n\u003ctd\u003e654 patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAlnylam’s BCG Matrix maps RNAi drugs by growth and share, showing where to invest, hold, or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAlnylam Pharmaceuticals, Inc. BCG Matrix: clear, one-page view to spot portfolio pain points fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Alnylam Pharmaceuticals, Inc. that helps validate key claims and supports faster, more confident decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGIVLAARI 2019 AHP approval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGIVLAARI won U.S. approval in 2019 for acute hepatic porphyria, a very rare, specialist-led disease with limited new patient flow. That keeps growth modest, but the product has a durable prescriber base and steady use in a niche market. In BCG terms, it fits a cash cow: low-growth, defensible, and still monetizing a proven launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOXLUMO 2020 PH1 approval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOXLUMO, approved in 2020 for primary hyperoxaluria type 1, fits a Cash Cow profile because PH1 is ultra-rare, affecting roughly 1 to 3 people per million, and patients need long-term therapy. That means low churn and steady repeat use, with no need for launch-level spending to keep the franchise running. Alnylam can keep the asset productive with limited commercial lift, which supports strong cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGIVLAARI mature rare-disease sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGIVLAARI is past launch and fits a mature cash cow: acute hepatic porphyria is a tiny market, but treated patients can stay on therapy long term, so share tends to stick. For Alnylam Pharmaceuticals, Inc., demand is about retention and refills, not fast market expansion. In a narrow rare-disease pool, steady sales matter more than new starts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOXLUMO mature rare-disease sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOXLUMO fits the \"cash cow\" box because it is already established in rare-disease care, with a broad global footprint and a focused diagnosed-patient pool that limits new growth. Its sales are steady rather than fast, and promotional spend stays contained, so it can keep high share without heavy launch costs. In Alnylam Pharmaceuticals, Inc.'s 2025 mix, that means mature, lower-growth revenue that still throws off cash. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal footprint already in place\u003c\/li\u003e\n\u003cli\u003eHigh share in diagnosed patients\u003c\/li\u003e\n\u003cli\u003eLow incremental promo burden\u003c\/li\u003e\n\u003cli\u003eSteady 2025 cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInclisiran royalty income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. still earns recurring royalty income from Novartis's Leqvio (inclisiran) partnership, while its own support costs stay limited. That makes the stream cash-cow-like: high-margin, low-capital income tied to a growing lipid-lowering drug with broad commercial reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring royalties, not heavy spend\u003c\/li\u003e\n\u003cli\u003eLeqvio growth supports future cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam’s Cash Cows: Rare-Drug Revenue Funding the Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn Alnylam Pharmaceuticals, Inc., GIVLAARI and OXLUMO fit Cash Cow traits: ultra-rare markets, sticky long-term use, and low launch-style spend. Leqvio royalties from Novartis add high-margin, recurring cash flow. In 2025, this mix means mature, low-growth revenue that still funds Alnylam Pharmaceuticals, Inc.'s pipeline.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eCash cow driver\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGIVLAARI\u003c\/td\u003e\n\u003ctd\u003eRare, recurring use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOXLUMO\u003c\/td\u003e\n\u003ctd\u003eUltra-rare, steady refills\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeqvio royalties\u003c\/td\u003e\n\u003ctd\u003eHigh-margin income\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAlnylam Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Alnylam Pharmaceuticals, Inc. BCG Matrix report you’ll receive after purchase. No demo content or hidden changes—just the full, polished document ready for strategic review. Once purchased, the same file is instantly available for download, use, and presentation. What you see here is exactly what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eONPATTRO 2018 legacy launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eONPATTRO was approved in 2018 for hATTR polyneuropathy, so it is Alnylam Pharmaceuticals, Inc.’s older TTR RNAi asset. With only 2 TTR RNAi drugs in the portfolio, AMVUTTRA has taken the growth role in the same market, leaving ONPATTRO as a legacy product with limited strategic upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eONPATTRO no ATTR-CM label\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eONPATTRO lacks the ATTR-CM label, so it cannot address the fastest-growing TTR segment while Alnylam Pharmaceuticals, Inc. pushes AMVUTTRA in that space. That leaves ONPATTRO tied to the older hATTR polyneuropathy market, which is smaller and slower. In BCG terms, low growth and a narrower addressable pool make ONPATTRO dog-like.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatisiran lifecycle decline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatisiran, the active ingredient in ONPATTRO, is a lifecycle-peak asset that now faces a shrinking role as Alnylam’s newer RNAi products scale. ONPATTRO needs IV dosing every 3 weeks, while AMVUTTRA offers quarterly dosing, so growth is harder and upkeep costs more than it returns. That fits a dog profile: mature, low-growth, and increasingly hard to defend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOlder alliance programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlder alliance programs in ocular and CNS R\u0026amp;D stayed noncommercial, so their market share was 0% and they did not build scale economics. In Alnylam Pharmaceuticals, Inc.’s FY2025 mix, value came from marketed products, while these legacy partners remained low-return assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eZero commercial launch\u003c\/li\u003e\n\u003cli\u003eNear-zero market share\u003c\/li\u003e\n\u003cli\u003eNo scale economics\u003c\/li\u003e\n\u003cli\u003eLow-return BCG \"dog\"\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInherited pre-commercial RNAi assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInherited pre-commercial RNAi assets at Alnylam Pharmaceuticals, Inc. still pull R\u0026amp;D time but have no near-term launch cash flow, so they sit in the Dog bucket. Legacy programs from Alnylam and Dicerna, which Alnylam bought for $3.3 billion in 2021, can keep spending alive without clear differentiation or timing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eHigh R\u0026amp;D drag, low monetization\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eNo launch timing, weak strategic pull\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eCash trap risk fits Dog classification\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eONPATTRO Lingers as Alnylam’s Slow-Moving Dog\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eONPATTRO, approved in 2018, is Alnylam Pharmaceuticals, Inc. older TTR RNAi asset and still needs IV dosing every 3 weeks.\u003c\/p\u003e\n\u003cp\u003eIt lacks the ATTR-CM label, so it stays tied to the smaller hATTR polyneuropathy market while AMVUTTRA takes the faster-growth role.\u003c\/p\u003e\n\u003cp\u003eLegacy ocular and CNS programs, plus Dicerna assets from the 2021 $3.3 billion deal, add R\u0026amp;D drag but little near-term cash, so they fit Dogs.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZilebesiran phase 3 hypertension\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHypertension is a huge market: the WHO says about 1.3 billion adults live with the condition worldwide, and long-acting RNAi could win share if outcomes hold. Zilebesiran is still investigational, so its current market share is 0, but phase 3 could open a large pool of patients needing fewer doses. For now, it fits the BCG \"Question Mark\" box: high-growth potential, no sales yet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFitusiran hemophilia program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFitusiran targets a hemophilia market worth over $10 billion, but the field is crowded with factor and non-factor therapies. The program moved late-stage to approval in 2025, yet safety, label limits, and physician adoption still cap uptake. With current share still small, the upside is real, but it fits Alnylam Pharmaceuticals, Inc. as a question mark.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCemdisiran complement disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCemdisiran sits in the Question Mark box because it is still in development and has 0% commercial share, while complement-mediated disease remains a growing field with strong demand. Its value depends on proving clear benefit versus entrenched and emerging rivals in a market where C5 and upstream complement drugs are already shaping competition. If Alnylam can show better efficacy, safety, or dosing, Cemdisiran could move from pipeline risk to a real franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eALN-HBV02 chronic hepatitis B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChronic hepatitis B is a huge market: WHO estimates 254 million people live with it, and about 1.1 million die each year. ALN-HBV02 is still investigational, so it has no market share or revenue yet. The upside is large, but the clinical and regulatory risk is also high, so this is a question mark.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e254 million patients worldwide\u003c\/li\u003e\n\u003cli\u003eHigh unmet need, zero revenue today\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eALN-HSD NASH\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALN-HSD sits in a huge liver market: MASLD\/NAFLD affects about 30% of adults worldwide, and MASH\/NASH is the high-value subset. The asset is still precommercial, so it has no revenue yet, and the key value driver is future proof in clinic, not sales today.\u003c\/p\u003e\n\u003cp\u003eThat makes it a classic question mark: the upside could be large if efficacy and safety land, but the clinical risk is still high. In BCG terms, it needs investment before it can move toward star status.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig market, no revenue\u003c\/li\u003e\n\u003cli\u003eClinical proof still missing\u003c\/li\u003e\n\u003cli\u003eHigh upside, high risk\u003c\/li\u003e\n\u003cli\u003eClear question-mark profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam’s Big-Bet Pipeline: Huge Markets, Zero Sales Moat—Yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc.’s Question Marks have big upside but no sales moat yet: Zilebesiran, Cemdisiran, ALN-HBV02, and ALN-HSD are still precommercial, so their market share is 0%. Their markets are large, from hypertension and complement disease to chronic hepatitis B and MASH, but each program still needs phase 3 or approval proof before revenue can scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZilebesiran\u003c\/td\u003e\n\u003ctd\u003ePhase 3\u003c\/td\u003e\n\u003ctd\u003eHypertension, 1.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCemdisiran\u003c\/td\u003e\n\u003ctd\u003eIn dev.\u003c\/td\u003e\n\u003ctd\u003eComplement disease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233975836937,"sku":"alny-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/alny-bcg-matrix.webp?v=1785710370","url":"https:\/\/dcfanalyst.com\/products\/alny-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}